Aquestive Therapeutics, Inc. SEC filings AQST
Aquestive Therapeutics, Inc. has 686 filings in SEC EDGAR's recent list, going back to May 14, 2007. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Jul 9, 2026 | — |
| S-3 | Shelf registration | Jun 26, 2026 | — |
| S-8 | Employee stock plan registration | Mar 4, 2026 | — |
| S-8 | Employee stock plan registration | Jan 21, 2026 | — |
| 424B5 | Prospectus supplement | Aug 14, 2025 | — |
| S-8 | Employee stock plan registration | Jan 24, 2025 | — |
| 424B2 | Prospectus | Apr 24, 2024 | — |
| 424B2 | Prospectus | Apr 24, 2024 | — |
| S-3 | Shelf registration | Apr 3, 2024 | — |
| 424B5 | Prospectus supplement | Mar 21, 2024 | — |
| 424B5 | Prospectus supplement | Mar 19, 2024 | — |
| S-8 | Employee stock plan registration | Feb 12, 2024 | — |
| 424B3 | Prospectus | Oct 2, 2023 | — |
| S-3 | Shelf registration | Sep 21, 2023 | — |
| S-8 | Employee stock plan registration | Aug 9, 2023 | — |
| S-8 | Employee stock plan registration | Jan 18, 2023 | — |
| 424B5 | Prospectus supplement | Sep 7, 2022 | — |
| 424B5 | Prospectus supplement | Jun 8, 2022 | — |
| 424B5 | Prospectus supplement | Apr 13, 2022 | — |
| S-8 | Employee stock plan registration | Jan 7, 2022 | — |
| S-3 | Shelf registration | Mar 26, 2021 | — |
| 424B5 | Prospectus supplement | Mar 26, 2021 | — |
| 424B5 | Prospectus supplement | Jan 21, 2021 | — |
| S-8 | Employee stock plan registration | Jan 8, 2021 | — |
| S-3 | Shelf registration | Jan 8, 2021 | — |
| 424B5 | Prospectus supplement | Mar 12, 2020 | — |
| 424B5 | Prospectus supplement | Dec 16, 2019 | — |
| 424B5 | Prospectus supplement | Dec 10, 2019 | — |
| 424B5 | Prospectus supplement | Sep 17, 2019 | — |
| 424B5 | Prospectus supplement | Sep 17, 2019 | — |
| S-3 | Shelf registration | Sep 11, 2019 | — |
| S-8 | Employee stock plan registration | Jul 27, 2018 | — |
| 424B4 | Prospectus | Jul 26, 2018 | — |
| S-1MEF | Form s-1mef | Jul 24, 2018 | — |
| S-1/A | Amended registration statement | Jul 20, 2018 | — |
| S-1/A | Amended registration statement | Jul 16, 2018 | — |
| S-1 | Registration statement | Jun 27, 2018 | — |
| S-1/A | Amended registration statement | Oct 3, 2007 | — |
| S-1/A | Amended registration statement | Sep 26, 2007 | — |
| S-1/A | Amended registration statement | Aug 29, 2007 | — |
| S-1/A | Amended registration statement | Jul 25, 2007 | — |
| S-1/A | Amended registration statement | Jun 26, 2007 | — |
| S-1 | Registration statement | May 14, 2007 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AQST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1398733
- Former names
- MonoSol Rx, Inc. (until Mar 27, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.